TOP TEN perturbations for 41514_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 41514_s_at
Selected probe(set): 209609_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 41514_s_at (209609_s_at) across 6673 perturbations tested by GENEVESTIGATOR:
Alzheimer's disease study 6 / normal large stellate neuron (entorhinal cortex)
Relative Expression (log2-ratio):-2.3350859Number of Samples:10 / 12
| Experimental | Alzheimer's disease study 6 |
| Large stellate neurons of the entorhinal cortex, collected from layer II of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal large stellate neuron (entorhinal cortex) |
| Large stellate neurons of the entorhinal cortex, collected from layer II of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |
pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)
Relative Expression (log2-ratio):-2.1568766Number of Samples:8 / 17
| Experimental | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (infant) |
| Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
breast cancer study 3 / normal organelle sample
Relative Expression (log2-ratio):2.052947Number of Samples:17 / 12
| Experimental | breast cancer study 3 |
| Breast basal tumor samples. | |
| Control | normal organelle sample |
| Normal organelle samples. |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):1.9586468Number of Samples:2 / 4
| Experimental | glioma study 17 (glioblastoma; unsorted) |
| Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):1.9161415Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.9073343Number of Samples:6 / 2
| Experimental | expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary) |
| Primary tumor tissue samples obtained from the breast of patients with malignant mucocarcinoid tumor. | |
| Control | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-1.8811417Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.8752022Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
vMyb overexpr. study 1 (adenovirus) / cMyb overexpr. study 2 (adenovirus)
Relative Expression (log2-ratio):-1.8565607Number of Samples:2 / 2
| Experimental | vMyb overexpr. study 1 (adenovirus) |
| Approximately 1x10^6 monocytes were infected with adenovirus expressing v-Myb and GFP for 16 hours, then total RNA was isolated. | |
| Control | cMyb overexpr. study 2 (adenovirus) |
| Approximately 1x10^6 monocytes were infected with adenovirus expressing c-Myb and GFP for 16 hours, then total RNA was isolated. |
pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)
Relative Expression (log2-ratio):1.8238649Number of Samples:9 / 8
| Experimental | pediatric septic shock study 3 (infant; subclass C) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate. | |
| Control | pediatric septic shock study 3 (infant; subclass A) |
| Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. |